COVID-19 in Cancer Patients: Patient Characteristics and Outcomes in the Post-COVID-19 Vaccination Period

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2024 May 30

PMID 38813483

Authors

Gulsen Iskender

Duygu Mert

Goknur Yapar Toros

Funda Yilmaz

Ersin Bozan

Semra Tuncbilek

Omur Berna Cakmak Oksuzoglu

Fevzi Altuntas

Mustafa Ertek

Affiliations

Soon will be listed here.

Abstract

Background/aim: It wasaimed herein to investigate coronavirus disease (COVID-19) in cancer patients and compare hematological and solid organ cancer patients in terms of the course and outcome of this disease.

Materials And Methods: Data from cancer patients with laboratory-confirmed COVID-19 infection were analyzed retrospectively. Risk factors for poor prognosis and the effect of vaccination on the clinical outcomes of the patients were evaluated.

Results: A total of 403 cancer patients who were diagnosed with COVID-19 between March 1st, 2021, and November 30th, 2022, were included, of whom 329 (81.6%) had solid and 74 (18.4%) had hematological cancers. Hospitalization and intensive care unit (ICU) admission rates were significantly higher in the hematological cancer patients compared to the solid organ cancer patients (73.0% vs. 35.9%, p< 0.001 and 25.7% vs. 14.0%, p= 0.013, respectively). The COVID-19related case fatality rate (CFR) was defined as 15.4%, and it was higher in the hematologicalcancer patientsthan inthe solid organ cancer patients (23.0% vs. 13.7%, p= 0.045) and was higher in patients with metastatic/advanced disease compared to the other cancer stages (p< 0.001). In the solid organ cancergroup, hospitalization, ICU admission, and the COVID-19 CFR were higher in patients with respiratory and genitourinary cancers (p< 0.001). A total of 288 (71.8%) patients had receivedCOVID-19 vaccination; 164 (56.94%) had≤2 doses and 124 (43.06%) had≥3 doses. The hospitalization rate was higher in patients with ≤2 doses of vaccine compared to those with ≥3 doses (48.2% vs. 29.8%,p= 0.002). Patients with COVID-19related death had higher levels of leucocyte, neutrophil, D-dimer, troponin, C-reactive protein (CRP), procalcitonin, and ferritin and lower levels of lymphocyte than the survivors. In the logistic regression analysis,the risk of COVID-19related mortality was higher in the hematological cancer patients(OR:1.726), those who were male (OR:1.757), and with the Pre-Delta/Delta variants (OR:1.817).

Conclusion: This study revealed that there is an increased risk of COVID-19-related serious events (hospitalization, ICU admission, or death) in patients with hematological cancerscompared with those who have solid organ cancers. It wasalso shown that receiving ≥3 doses of COVID-19 vaccine is more protective against severe illness and the need for hospitalization than ≤2 doses.

References

Basci S, Ata N, Altuntas F, Yigenoglu T, Dal M, Korkmaz S . Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med. 2021; 17(1):135-139. PMC: 8190567. DOI: 10.1007/s11739-021-02784-y. View

Lauring A, Tenforde M, Chappell J, Gaglani M, Ginde A, McNeal T . Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376:e069761. PMC: 8905308. DOI: 10.1136/bmj-2021-069761. View

Giesen N, Busch E, Schalk E, Beutel G, Ruthrich M, Hentrich M . AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. Eur J Cancer. 2023; 181:102-118. PMC: 9737523. DOI: 10.1016/j.ejca.2022.11.030. View

Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P . Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. EBioMedicine. 2021; 74:103705. PMC: 8629680. DOI: 10.1016/j.ebiom.2021.103705. View

Stoss C, Steffani M, Pergolini I, Hartmann D, Radenkovic D, Novotny A . Impact of the COVID-19 Pandemic on Surgical Oncology in Europe: Results of a European Survey. Dig Surg. 2021; 38(4):259-265. PMC: 8247801. DOI: 10.1159/000515186. View

Bakouny Z, Hawley J, Choueiri T, Peters S, Rini B, Warner J . COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020; 38(5):629-646. PMC: 7528740. DOI: 10.1016/j.ccell.2020.09.018. View

Zarifkar P, Kamath A, Robinson C, Morgulchik N, Shah S, Cheng T . Clinical Characteristics and Outcomes in Patients with COVID-19 and Cancer: a Systematic Review and Meta-analysis. Clin Oncol (R Coll Radiol). 2020; 33(3):e180-e191. PMC: 7674130. DOI: 10.1016/j.clon.2020.11.006. View

Fenioux C, Teixeira L, Fourati S, Melica G, Lelievre J, Gallien S . SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. JAMA Oncol. 2022; 8(4):612-617. PMC: 8742219. DOI: 10.1001/jamaoncol.2021.7777. View

Bestvina C, Whisenant J, Torri V, Cortellini A, Wakelee H, Peters S . Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clin Res Rep. 2022; 3(8):100335. PMC: 9119707. DOI: 10.1016/j.jtocrr.2022.100335. View

10.

Altuntas F, Ata N, Yigenoglu T, Basci S, Dal M, Korkmaz S . COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2020; 56(4):952-955. DOI: 10.1038/s41409-020-01084-x. View

11.

Lee M, Peng S, Lee A, Wong S, Tay R, Li J . Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. Ann Acad Med Singap. 2023; 52(1):8-16. View

12.

Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M . COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021; 14(1):168. PMC: 8515781. DOI: 10.1186/s13045-021-01177-0. View

13.

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

14.

Yasin A, Goktas Aydin S, Sumbul B, Koral L, Simsek M, Geredeli C . Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. Future Oncol. 2022; 18(10):1235-1244. PMC: 8793921. DOI: 10.2217/fon-2021-1248. View

15.

Seneviratne S, Wijerathne W, Yasawardene P, Somawardana B . COVID-19 in cancer patients. Trans R Soc Trop Med Hyg. 2022; 116(9):767-797. PMC: 8992310. DOI: 10.1093/trstmh/trac015. View

16.

Plais H, Labruyere M, Creutin T, Nay P, Plantefeve G, Tapponnier R . Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. Front Oncol. 2022; 12:858276. PMC: 8960921. DOI: 10.3389/fonc.2022.858276. View

17.

Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu C . Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncol. 2022; 9(1):128-134. PMC: 9634600. DOI: 10.1001/jamaoncol.2022.5357. View

18.

Parohan M, Yaghoubi S, Seraji A, Hassan Javanbakht M, Sarraf P, Djalali M . Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. Aging Male. 2020; 23(5):1416-1424. DOI: 10.1080/13685538.2020.1774748. View

19.

Gounant V, Ferre V, Soussi G, Charpentier C, Flament H, Fidouh N . Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. J Thorac Oncol. 2021; 17(2):239-251. PMC: 8593625. DOI: 10.1016/j.jtho.2021.10.015. View

20.

Ferrari B, Ferreira C, Menezes M, De Marchi P, Canedo J, de Melo A . Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil. JCO Glob Oncol. 2021; 7:46-55. PMC: 8081500. DOI: 10.1200/GO.20.00444. View